[Correspondence] PD-1 inhibition in sarcoma still needs investigation

In their Article, Hussein Tawbi and colleagues1 suggest that pembrolizumab might have clinical activity in patients with undifferentiated pleomorphic sarcoma or dedifferentiated liposarcoma. However, the SARC028 trial was not designed to specifically assess the activity of pembrolizumab in undifferentiated pleomorphic sarcoma or dedifferentiated liposarcoma, and this study was negative for its primary endpoint.

http://ift.tt/2C7ZtrE